These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 6103187)

  • 1. Sulphinpyrazone, aspirin, and uric acid.
    Newland HR
    Lancet; 1980 Apr; 1(8171):770. PubMed ID: 6103187
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings: The effect of sulphinpyrazone, sodium aspirin and oxprenolol on the formation of arterial platelet thrombi.
    Lewis GP; Westwick J
    Br J Pharmacol; 1975 Oct; 55(2):255P-256P. PubMed ID: 1201396
    [No Abstract]   [Full Text] [Related]  

  • 3. Sulphinpyrazone prevents in vivo the inhibitory effect of aspirin on rat platelet cyclo-oxygenase activity.
    Rajtar G; Cerletti C; Livio M; de Gaetano G
    Biochem Pharmacol; 1981 Oct; 30(20):2773-6. PubMed ID: 6797431
    [No Abstract]   [Full Text] [Related]  

  • 4. Mechanisms of Forssman-induced bronchospasm and their inhibition.
    Butler KD; Smith JR
    Br J Pharmacol; 1981 May; 73(1):25-32. PubMed ID: 7284697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence for a postsecretory reabsorptive site for uric acid in man.
    Diamond HS; Paolino JS
    J Clin Invest; 1973 Jun; 52(6):1491-9. PubMed ID: 4703233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of sulphinpyrazone (Anturan) on uric acid excretion and plasma uric acid concentration in healthy volunteers.
    Pfister B; Imhof P; Wirz H
    Eur J Clin Pharmacol; 1978 Jun; 13(4):263-5. PubMed ID: 668783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sulphinpyrazone and aspirin on gastrointestinal blood loss in man.
    Dawson A; Lavinski C; Parsons V; Weston MJ
    Thromb Res; 1978 May; 12(5):947-50. PubMed ID: 307835
    [No Abstract]   [Full Text] [Related]  

  • 8. Evidence for a post-secretory reabsorptive site for uric acid in man.
    Diamond HS; Sharon E
    Adv Exp Med Biol; 1974; 41():745-9. PubMed ID: 4832604
    [No Abstract]   [Full Text] [Related]  

  • 9. The effect of mefenamic acid and flufenamic acid on plasma uric acid levels.
    Latham BA; Radcliff F; Robinson RG
    Ann Phys Med; 1966 Aug; 8(7):242-3. PubMed ID: 5918265
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of drugs on the binding of urate to human albumin.
    Bluestone R; Kippen I; Whitehouse M; Klinenberg JR
    Clin Sci; 1970 Jan; 38(1):1P. PubMed ID: 5411474
    [No Abstract]   [Full Text] [Related]  

  • 11. Mode of action of currently used antiplatelet drugs.
    de Gaetano G; Bertele' V; Cerletti C
    Agents Actions Suppl; 1986; 20():191-201. PubMed ID: 3101442
    [No Abstract]   [Full Text] [Related]  

  • 12. Platelets, cardiac valves and sulphinpyrazone.
    Loeliger EA
    Thromb Haemost; 1982 Apr; 47(2):189. PubMed ID: 7101242
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of aspirin and sulfinpyrazone on platelet prostaglandin synthesis.
    McDonald JW; Stuart RK; Barnett HJ
    Adv Exp Med Biol; 1977; 82():222-4. PubMed ID: 920363
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of platelet-modifying drugs on arterial thromboembolism in baboons. Aspirin potentiates the antithrombotic actions of dipyridamole and sulfinpyrazone by mechanism(s) independent of platelet cyclooxygenase inhibition.
    Hanson SR; Harker LA; Bjornsson TD
    J Clin Invest; 1985 May; 75(5):1591-9. PubMed ID: 3923041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of sulphinpyrazone and aspirin on platelet adhesion to subendothelium following oral administration to rabbits.
    Davies JA; Menys VC
    Thromb Res; 1981 Feb 15-Mar 1; 21(4-5):329-37. PubMed ID: 7268688
    [No Abstract]   [Full Text] [Related]  

  • 16. The pharmacology of the hypouricemic effect of benzbromarone.
    Fox IH; Sinclair DS
    Adv Exp Med Biol; 1977; 76B():328-33. PubMed ID: 855759
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link.
    de Gaetano G; Cerletti C; Bertelè V
    Lancet; 1982 Oct; 2(8305):974-7. PubMed ID: 6127469
    [No Abstract]   [Full Text] [Related]  

  • 18. Status of antiplatelet drugs in coronary heart disease.
    Mehta J; Mehta P
    JAMA; 1979 Jun; 241(24):2649-51. PubMed ID: 439365
    [No Abstract]   [Full Text] [Related]  

  • 19. A pharmacokinetic and platelet function study of the combined administration of metoprolol and sulfinpyrazone to healthy volunteers.
    Cortellaro M; Boschetti C; Antoniazzi V; Polli EE; de Gaetano G; De Blasi A; Gerna M; Pezzi L; Garattini S
    Thromb Res; 1984 Apr; 34(1):65-74. PubMed ID: 6729769
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of sulphinpyrazone and aspirin on latelet adhesion to activated charcoal and dialysis membranes in vitro.
    Winchester JF; Forbes CD; Courtney JM; Reavey M; Prentice CR
    Thromb Res; 1977 Oct; 11(4):443-51. PubMed ID: 335561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.